About Technology Products Partners Careers News Contact News Enara Bio to present progress of research on novel, cancer-specific, MR1-restricted TCRs at upcoming TCR-based Therapies Summit Dr. Rachel Abbott, Head of TCR Pipeline and Dark Antigen Research at Enara Bio, will present at the 2nd TCR-based Therapies Summit on 9 June. 28th September 2021 Enara Bio announces the appointment of highly experienced biotech executive Dr. Robert Ang to its Board of Directors Enara Bio announces the appointment of Dr. Robert Ang to the Company’s Board of Directors as an independent non-executive director 21st June 2021 Enara Bio participates in Boehringer Ingelheim’s “Taking Cancer On” podcast series Enara Bio is pleased to have participated in Boehringer Ingelheim’s “Taking Cancer On” podcast series, launched today. 9th March 2021 Enara Bio adds further cell therapy and TCR expertise to its Senior Research Team Dr Mark Creighton-Gutteridge appointed as Vice President, Head of Research Dr Rachel Abbott appointed as Head of TCR Pipeline and Dark Antigen Research 12th January 2021 Boehringer Ingelheim and Enara Bio enter Strategic Collaboration and Licensing Agreement to discover novel shared antigens for cancer immunotherapies Collaboration focuses on up to three types of lung and gastrointestinal (GI) cancers. Latest in a series of strategic acquisitions and partnerships that strengthens Boehringer Ingelheim’s position in the cancer vaccine and T-cell engager spaces. ﻿Agreement and partnership with Boehringer Ingelheim provides additional validation of Enara Bio’s EDAPT™ platform and Dark Antigen™ discovery work and supports ongoing cell therapy based therapeutic approach. 16th December 2020 Enara Bio adds further world-class cell therapy and immuno-oncology expertise to Senior Management Team and Scientific Advisory Board Dr Erik Rutjens appointed as Vice President, Cell Therapy Operations Dr Sadik Kassim and Dr Michael Quigley strengthen Scientific Advisory Board with deep industry experience 9th December 2020 Enara Bio relocates to The Oxford Science Park’s newest facility to expand R&D capabilities in the search for novel cancer immunotherapies Enara’s move from the Oxford BioEscalator to one of the UK's largest biomedical innovation centres is in preparation for its future growth and ambition to transform cancer care. The dedicated research facility will enable the company to accelerate the preclinical development of its lead MR1-targeting T-cell therapy program. 3rd November 2020 Enara Bio to present progress in Dark Antigen™ research at upcoming Neoantigen-Based Therapies Summit Enara Bio, a biotechnology company leveraging its proprietary T-cell/T-cell receptor (TCR) discovery and Dark Antigen™ platforms to deliver targeted cancer immunotherapies, will present at the 5th Neoantigen Based Therapies Summit on November 5. 3rd June 2020 Ervaxx rebrands as Enara Bio to reflect a broader emphasis on the discovery and development of novel TCR-based cancer immunotherapies This new name reflects the company’s expanded product discovery and development strategy beyond its initial focus on endogenous retroviral (ERV) antigens for the development of cancer vaccines (hence “Ervaxx”). 24th January 2020 Ervaxx and Cardiff University enter collaboration to develop novel T-cell and T-cell receptor-based immunotherapeutics targeting Dark Antigens™ Collaboration also focuses on exciting research published earlier this week in Nature Immunology identifying MR1 as a target for novel anti-cancer immunotherapies Enara Bio About Technology Products Partners Careers News Contact Legal Website Terms Privacy Policy © 2021 Enara Bio | All rights reserved Enara Bio, Dark Antigen and EDAPT are trademarks of Enara Bio Limited Site by Ether